ALLERGAN, Inc. (NY:AGN)
58.62
0.03 (0.05%)
| ALLERGAN, Inc. (NY:AGN) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $58.65 | 52 Week High | $60.85 | ||
| Open | $58.13 | 52 Week Low | $28.95 | ||
| Day High | $58.82 | P/E | 32.39 | ||
| Day Low | $58.13 | EPS | $1.81 | ||
| Volume | 1,239,540 | ||||
| More AGN Info: Chart SEC Filings Profile Historical Options | |||||
Allergan Inc. Summary
Allergan, Inc. develops and commercializes pharmaceutical and medical device products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, and other specialty markets worldwide.
Executives
David E.I. Pyott - Chairman, CEO
Links
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| ARM | 11 | GR | 11 |
| RAND | 10 | SWN | 10 |
| TLVT | 10 | CL | 10 |
| RDSA | 10 | MEO | 10 |
| PG | 10 | EVN | 10 |
| XB | 10 | SAN | 10 |
Entities who have mentioned AGN
- Citi | View Related Stories »
- Credit Suisse | View Related Stories »
- HSBC | View Related Stories »
- Carl Icahn | View Related Stories »
- Vanguard | View Related Stories »
- Dividend | View Related Stories »
- Deutsche Bank | View Related Stories »
- UBS | View Related Stories »
- Piper Jaffray | View Related Stories »
- Goldman Sachs | View Related Stories »
- Morgan Stanley | View Related Stories »
- Trading Radar | View Related Stories »
- Jefferies & Co | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Scopia Capital | View Related Stories »
- Argus | View Related Stories »
- William Blair | View Related Stories »
- Lehman Brothers | View Related Stories »
- Cowen & Co | View Related Stories »
- S&P Equity Research | View Related Stories »
- Bear Stearns | View Related Stories »
- Longbow Research | View Related Stories »
- Robert W Baird | View Related Stories »
- Needham & Co | View Related Stories »
- Morningstar, Inc. | View Related Stories »
View All Major News StreetInsider.com Major News for AGN
- Allergan (AGN) Posts Q3 EPS of $1.13, Topping Street; Guides FY09
- Allergan (AGN) Tops Q2 Views; Guides Q3, FY09; Declares $0.05 Qtr. Dividend
- Allergan (AGN) Reports Mixed Q1 Earnings; Guides Q2, Reaffirms FY09 Outlook; Declares $0.06/Share Qtr. Dividend
View All ReportsStreetInsider.com Reports on AGN
- Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
- Allergan (AGN) Posts Q3 EPS of $1.13, Topping Street; Guides FY09
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Allergan (AGN) Wins ALPHAGAN P Patent Infringement Lawsuit
- Brean Murray Downgrades St. Jude Medical (STJ) to Hold
View All Press ReleasesCompany Press Releases on AGN
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
- Don't Miss Out! The Registration Period for the 2010 IR Global Rankings Ends TOMORROW!
- Allergan Reports Third Quarter 2009 Operating Results
StreetInsider Reports on AGN by Category
View All BlogsBlogs on AGN
- Earnings highlights: Aetna, Allergan, E*Trade, Goodyear, RadioShack, SAP, Visa ...
- Pharma earnings recap: Mylan, Allergan, Novo-Nordisk
- Healthcare Profits: Rating Company Sensitivity to Obamacare
- Healthcare Profits: Assessing Company Sensitivity to Obamacare
- Allergan Q3 2009 Earnings Call Transcript
View All FilingsSEC Filings on AGN
- Form 4 HERBERT GAVIN S For: Nov 10
- Form 4 EDWARDS JEFFREY L For: Nov 06
- Form 4 Diradoorian Raymond H For: Nov 05
- Form 10-Q ALLERGAN INC For: Sep 30
- Form 4 GALLAGHER MICHAEL R For: Nov 03
Comments on recent AGN articles
Comments on AGN
No comments are currently available.
on Jul 26, 2009
at 03:45 PM allergan With their cosmetic and new eye and urinary meds I see Allergan going to 72
Article: Citi Upgrades Allergan (AGN) to Buy